Seattle Genetics and Genentech have expanded their antibody-drug conjugate (ADC) collaboration. Genentech will pay an upfront fee of $12 million for rights to use Seattle Genetics’ ADC technology with additional antigens to be named by Genentech. ADCs are monoclonal antibodies that selectively deliver potent anti-cancer agents to tumor cells. Genentech is responsible for research, preclinical and clinical development, manufacturing and commercialization of ADCs; Seattle Genetics is eli...